Contribution of platelets to tumour metastasis.
TLDR
Contributions of platelets to tumour cell survival and spread suggest platelets as a new avenue for therapy.Abstract:
Experimental evidence suggests that platelets contribute to metastasis through adhesive and haemostatic functions that promote cancer cell survival, immune evasion and interactions with vascular cells to assist organ colonization from the bloodstream. Extensive experimental evidence shows that platelets support tumour metastasis. The activation of platelets and the coagulation system have a crucial role in the progression of cancer. Within the circulatory system, platelets guard tumour cells from immune elimination and promote their arrest at the endothelium, supporting the establishment of secondary lesions. These contributions of platelets to tumour cell survival and spread suggest platelets as a new avenue for therapy.read more
Citations
More filters
Journal ArticleDOI
Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.
TL;DR: The intention-to-treat random-effects meta-analysis showed that once-only flexible sigmoidoscopy screening performed on average-risk individuals aged 55 + decreased CRC incidence by 18% and mortality by 28%, but sex-specific results were lacking.
Journal ArticleDOI
Thrombocytosis: a retrospective study of 165 dogs
TL;DR: Thrombocytosis in dogs occurred most frequently secondary to neoplastic and inflammatory diseases and was commonly associated with glucocorticoid and vincristine administration.
Journal ArticleDOI
An RGD motif present in cadherin 17 induces integrin activation and tumor growth
Rubén Álvaro Bartolomé,Alberto Peláez-García,Inmaculada Gomez,Sofia Torres,María Jesús Fernández-Aceñero,Beatriz Escudero-Paniagua,J. Ignacio Imbaud,J. Ignacio Casal +7 more
TL;DR: The RGD binding motif constitutes a switch for integrin pathway activation and shows a novel capacity of CDH17 as an integrin ligand, the first known integrin-ligand RGD-cadherin.
Journal ArticleDOI
Activation of Pro-uPA Is Critical for Initial Escape from the Primary Tumor and Hematogenous Dissemination of Human Carcinoma Cells
Erin M. Bekes,Elena I. Deryugina,Tatyana A. Kupriyanova,Ewa Zajac,Kenneth A. Botkjaer,Peter A. Andreasen,James P. Quigley +6 more
TL;DR: In this article, the authors used a highly disseminating variant of the human PC-3 prostate carcinoma cell line, PC-hi/diss, as a prototype of aggressive carcinomas to investigate the mechanisms whereby pro-uPA activation and uPA-generated plasmin functionally contribute to specific stages of metastasis.
Journal ArticleDOI
TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer.
TL;DR: Findings show that the TIMP1 mRNA in platelets is a potential independent diagnostic biomarker for colorectal cancer, and that platelets can carry RNAs into coloreCTal cancer cells to promote colorectoral cancer development.
References
More filters
Journal ArticleDOI
Tumor Angiogenesis: Therapeutic Implications
TL;DR: This new capillary growth is even more vigorous and continuous than a similar outgrowth of capillary sprouts observed in 2016 and is likely to be accompanied by neovascularization.
Journal ArticleDOI
Cancer Metastasis: Building a Framework
Gaorav P. Gupta,Joan Massagué +1 more
TL;DR: Understanding of the origins and nature of cancer metastasis and the selection of traits that are advantageous to cancer cells is promoted.
Journal ArticleDOI
Dissemination and growth of cancer cells in metastatic sites
TL;DR: Inhibition of the growth of metastases in secondary sites offers a promising approach for cancer therapy and could help to improve the treatment of metastatic disease.
Journal ArticleDOI
Microenvironmental regulation of metastasis
TL;DR: Experimental data demonstrating the role of the microenvironment in metastasis is described, areas for future research are identified and possible new therapeutic avenues are suggested.
Journal ArticleDOI
Integrins in cancer: biological implications and therapeutic opportunities
TL;DR: Clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.